Thomas de Vlaam
Private Equity Investor bij Pillar Co Management LLC
Profiel
Mr. Thomas de Vlaam is a Partner at Pillar Co Management LLC.
Mr. de Vlaam was previously employed as a Founder & CEO by Amylon Therapeutics BV.
He received his undergraduate degree from the University of Groningen.
Actieve functies van Thomas de Vlaam
| Bedrijven | Functie | Begin |
|---|---|---|
Pillar Co Management LLC
 Pillar Co Management LLC Investment ManagersFinance Pillar Co Management LLC (Pillar VC) is a venture capital firm founded in 2016 by Jamie Goldstein. The firm is headquartered in Boston, Massachusetts. | Private Equity Investor | 01-07-2022 |
Eerdere bekende functies van Thomas de Vlaam
| Bedrijven | Functie | Einde |
|---|---|---|
Amylon Therapeutics BV
 Amylon Therapeutics BV Pharmaceuticals: MajorHealth Technology Amylon Therapeutics BV is a biopharmaceutical company, which engages in the research and development of therapies for the central nervous system. It specializes in ribonucleic acid modulation technology to target rare genetic disorders. The company was founded by Thomas de Vlaam and is headquartered in Leiden, the Netherlands. | Algemeen Directeur | 31-05-2022 |
Opleiding van Thomas de Vlaam
| University of Groningen | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 2 |
|---|---|
Pillar Co Management LLC
Pillar Co Management LLC Investment ManagersFinance Pillar Co Management LLC (Pillar VC) is a venture capital firm founded in 2016 by Jamie Goldstein. The firm is headquartered in Boston, Massachusetts. | Finance |
Amylon Therapeutics BV
Amylon Therapeutics BV Pharmaceuticals: MajorHealth Technology Amylon Therapeutics BV is a biopharmaceutical company, which engages in the research and development of therapies for the central nervous system. It specializes in ribonucleic acid modulation technology to target rare genetic disorders. The company was founded by Thomas de Vlaam and is headquartered in Leiden, the Netherlands. | Health Technology |